Cargando…
Consideration of dornase alfa for the treatment of severe COVID-19 acute respiratory distress syndrome
We propose a likely contribution to severe COVID-19 morbidity by extracellular DNA in neutrophil extracellular traps (NETs). Dornase alfa degrades extracellular DNA to reduce mucus rigidity and accumulation, and was associated with respiratory improvement in a first patient. Dornase alfa should be c...
Autores principales: | Earhart, A.P., Holliday, Z.M., Hofmann, H.V., Schrum, A.G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7192073/ https://www.ncbi.nlm.nih.gov/pubmed/32355564 http://dx.doi.org/10.1016/j.nmni.2020.100689 |
Ejemplares similares
-
Non-Randomized Trial of Dornase Alfa for Acute Respiratory Distress Syndrome Secondary to Covid-19
por: Holliday, Zachary M., et al.
Publicado: (2021) -
The use of dornase alfa in patients with COVID-19
por: Ramachandram, Dinesh Sangarran, et al.
Publicado: (2023) -
Neutrophils and secondary infections in COVID-19 induced acute respiratory distress syndrome
por: Holliday, Z.M., et al.
Publicado: (2021) -
The Use of Dornase Alfa in the Management of COVID-19-Associated Adult Respiratory Distress Syndrome
por: Toma, Andrew, et al.
Publicado: (2021) -
Aerosol Delivery of Dornase Alfa Generated by Jet and Mesh Nebulizers
por: Chang, Kyung Hwa, et al.
Publicado: (2020)